Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-04-01

Study Completion Date

2027-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly diagnosed cancer cases in Switzerland and affect more than 12,000 individuals annually. Several hundred of these patients are likely to carry known genetic mutations associated with HBOC or LS. Genetic testing for hereditary susceptibility to cancer can prevent many cancer deaths through early identification and engagement in high-risk management care that involves intensive surveillance, chemoprevention and/or prophylactic surgery. However, current rates of genetic testing indicate that many Swiss mutation carriers and their family members do not use cancer genetic services (counseling and/or testing), either due to lack of coordination of care or due to lack of communication about the mutation among family members.

Cascade screening identifies and tests family members of a known mutation carrier. It determines whether asymptomatic family members are carriers of the identified mutation and proposes management options to reduce harmful outcomes. Robust evidence of basic science and descriptive population-based studies in Switzerland support the necessity of cascade screening for HBOC and LS. However, translation of this knowledge into public health interventions is lacking.

Specific Aims of the CASCADE study are:

1. Survey Index Patients diagnosed with HBOC or LS from clinic-based genetic testing records and determine their cancer status and surveillance practices; needs for coordination of medical care; psychosocial needs; patient-provider and patient-family communication needs; quality of life; willingness to serve as advocates for cancer genetic services for blood relatives.
2. Survey first- and second-degree relatives, and first cousins identified from pedigrees and/or family history records of HBOC and LS Index Patients and determine their cancer and mutation status; cancer surveillance practices; needs for coordination of medical care; barriers and facilitators to using cancer genetic services; psychosocial needs; patient-provider and patient-family communication needs; quality of life; willingness to participate in a study designed to increase use of cancer genetic services.
3. Explore the influence of patient-provider communication about genetic cancer risk on patient-family communication and the acceptability of a family-based communication, coping, and decision support intervention with focus group(s) of mutation carriers and blood relatives.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome

NCT04009148

BRCA-Mutated Ovarian Carcinoma BRIP1 Gene Mutation MSH2 A636P +5 more

ACTIVE_NOT_RECRUITING

Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome

NCT04508764

Hereditary Breast and Ovarian Cancer Lynch Syndrome

TERMINATED NA

Identifying and Caring for Individuals With Inherited Cancer Syndrome

NCT04494945

BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome Breast Ductal Carcinoma In Situ Hematopoietic and Lymphoid System Neoplasm +3 more

RECRUITING NA

Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes

NCT06914726

Hereditary Breast/Ovarian Cancer (brca1, brca2) Lynch Syndrome Genetic Variation +2 more

ENROLLING_BY_INVITATION NA

Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer

NCT02560818

Breast Cancer Transcriptomes Molecular Diagnostic +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Please see study protocol provided in the references

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary Breast and Ovarian Cancer Lynch Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CASCADE genetic screening

Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Carrier of a mutation associated with HBOC or LS
2. Have at least one living blood relative
3. Men and women
4. 18 years old and older
5. Mentally and physically able to provide informed consent
6. Can read and speak German or French or Italian or English
7. Currently living in Switzerland.

Exclusion Criteria

1. Carriers of unclassified variants (VUS) in BRCA1, BRCA2 or MLH1, MSH2, MSH6, PMS2, EPCAM genes
2. Not living in Switzerland
3. Patients who are critically ill and cannot complete the CASCADE survey
4. Participants who are institutionalized (e.g., nursing homes) or incarcerated

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No